No abstract

Systemic lupus erythematosus (SLE) is associated with multi-organ damage including cardiac valve, which may need valvular operation. However, methods for outcome prediction and prosthetic valve selection are unclear in SLE patients undergoing cardiac valve surgery. Twenty-five SLE patients receiving valvular operation in a single institute between 2002 and 2020 were enrolled. SLICC/ACR damage index (SDI) was applied to evaluate the damage severity. Clinical outcomes were compared between patients with different SDI. The hospital survival rate was 88%, and long-term survival rate was 59.5% and 40.2% at five and ten years. The median SDI was 4 (IQR 3–6) in our study, patients were then grouped into higher SDI (defined as SDI ≥ 5, n = 11) and lower SDI group (defined as SDI < 5, n = 14). The in-hospital survival rate (72.2% vs 100%, p = 0.074), and five-year survival rate (18.2% vs 92.9%, p < 0.001) was lower in higher SDI group, compared to lower SDI group. SDI score was associated with long-term outcome for SLE patients receiving cardiac valve surgery. SDI ≥ 5 was associated with very poor long-term outcomes. This finding implicates that xenograft might be a reasonable choice for SLE patients with SDI ≥ 5.

After stratifying patients by percentage of LKB1 expression, cutoff of 20% showed a tendency to increase OS in patients with 20% expression (figure 1); 49.9 months (IC 95%, 10.6-85.2 months) vs 29.5 months (IC 95%, 26.3-32.7 months), (p¼0.068). Furthermore, a similar trend in OS was observed in patients with 50% expression, median OS was not reached compared with 29.5 months (IC 95%, 26.2-32.7 months) in patients with <50% expression (p¼0.091). Conclusion: We found a trend to higher OS in patients with LKB1 expression >20%. This data should be confirmed in prospective study in order to determine the role of LKB1 as biomarker in NSCLC patients.

Errors occurred in Table 2, "Association between STAS and clinicopathological characteristics and genetic mutations" which are corrected here. Specifically, the patient number of T1mi and T1a were 61 and 103, respectively. Positive STAS was noted in 11.7% (12/103) of T1a patients, and was not noted in all T1mi patients.